Yazar "Jokubaitis, Vilija" için listeleme
-
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Hughes, Jordana; Jokubaitis, Vilija; Lugaresi, Alessandra; Hupperts, Raymond; Izquierdo, Guillermo; Prat, Alexandre; Spitaleri, Daniele (Amer Medical Assoc, 2018)IMPORTANCE The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested. OBJECTIVE To examine the association of superimposed relapses in ... -
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
Spelman, Tim; Kalincik, Tomas; Jokubaitis, Vilija; Zhang, Annie; Pellegrini, Fabio; Wiendl, Heinz; Lechner-Scott, Jeannette (Lippincott Williams & Wilkins, 2016)Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS) initiating natalizumab compared with interferon-beta (IFN-beta)/glatiramer acetate ... -
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Luis Sanchez-Menoyo, Jose (Amer Medical Assoc, 2015)IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is ... -
Defining reliable disability outcomes in multiple sclerosis
Kalincik, Tomas; Cutter, Gary; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Ramo, Cristina (Oxford Univ Press, 2015)Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on progression of Expanded Disability ... -
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Turkoglu, Recai (Sage Publications Ltd, 2020)Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and ... -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ... -
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalincik, Tomas; Manouchehrinia, Ali; Sobisek, Lukas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Iuliano, Gerardo (Oxford Univ Press, 2017)Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response ...
